Steven C. Mayer is the former CEO of Teva Pharmaceuticals USA, one of the world’s leading generic pharmaceutical companies. The company’s mission is to play a leading role in the transformation of the U.S. health care system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals.
He formerly served as CEO of CoGenesys Inc., a privately owned biopharmaceutical company that he co-founded in 2005. CoGenesys was acquired by Teva in 2008.
Prior to joining CoGenesys, Mr. Mayer was executive vice president and chief financial officer of Human Genome Sciences Inc. (HGS). During his tenure at HGS, he raised more than $3 billion in equity, debt and facilities financing.
He previously served as vice president and chief financial officer of GenVec Inc., an early stage gene-therapy company, and vice president and chief financial officer for TheraTech Inc., a leading drug-delivery company.Mr. Mayer holds an MBA from Stanford University and a BA in economics from Williams College.
Broaddus & Associates
Mr. Nicholas is a senior executive in the field of healthcare real estate and facilities development, where he has leveraged his engineering background in 30 years of business leadership and project management. He has applied an Owner’s perspective in all aspects of the planning, design and construction of Capital Improvement Projects for over 30 healthcare clients in 10 states. He has provided leadership to program development at such renowned institutions as Johns Hopkins Medicine, University of Pittsburgh Medical Center, Children’s Hospital of Philadelphia, University of Pennsylvania Medical Center, University of Medicine and Dentistry of NJ and several others.
Jeff holds a Bachelor of Science degree in Mechanical Engineering from University of Connecticut and is a licensed Professional Engineer in Wisconsin.